Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats

Canadian Journal of Physiology and Pharmacology

Volumn 88, Issue 6, 2010, Pages 636-643

  Cavasin, Maria A ^a,b   Semus, Hillary ^b   Pitts, Kelly ^c   Peng, Yanyu ^b   Sandoval, Jennifer ^b   Chapo, Joseph ^b   Plato, Craig F ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b GILEAD SCIENCES   (United States)

^c AMGEN INC   (United States)

Author keywords

Cirrhosis; Endothelin; Hepatic flow; Hepatic hemodynamics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BOSENTAN; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; OLIGOPEPTIDE; PIPERIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL; ARTICLE; BLOOD; BLOOD FLOW; BLOOD PRESSURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HEMODYNAMICS; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RAT; SPRAGUE DAWLEY RAT; STELLATE CELL; VASCULARIZATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GENE EXPRESSION; HEMODYNAMICS; HEPATIC STELLATE CELLS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MALE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; SULFONAMIDES;

EID: 79952278449     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y10-038     Document Type: Article

References (32)

1. Angus, P.W. 2006. Role of endothelin in systemic and portal resistance in cirrhosis. Gut, 55(9): 1230-1232. doi:10.1136/gut.2005.088633. PMID:16905694.
2. Bauer, M., Bauer, I., Sonin, N.V., Kresge, N., Baveja, R., Yokoyama, Y., et al. 2000. Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver. Hepatology, 31(4): 937-947. doi:10.1053/he.2000.5922. PMID:10733551.
3. Cahill, P.A., Hou, M.C., Hendrickson, R., Wang, Y.N., Zhang, S., Redmond, E.M., and Sitzmann, J.V. 1998. Increased expression of endothelin receptors in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics. Hepatology, 28(2): 396-403. doi:10.1002/hep.510280216. PMID:9696003.
4. Chan, C.C., Wang, S.S., Lee, F.Y., Chang, F.Y., Lin, H.C., Hou, M.C., et al. 2004. Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats. Eur. J. Clin. Invest. 34(4): 290-296. doi:10.1111/j.1365-2362.2004.01336.x. PMID:15086361.
5. De Gottardi, A., Shaw, S., Sägesser, H., and Reichen, J. 2000. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats. J. Hepatol. 33(5): 733-737. doi:10.1016/S0168-8278(00)80303-7. PMID:11097480.
6. Feng, H.Q., Weymouth, N.D., and Rockey, D.C. 2009. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 297(1): G27-G33. doi:10.1152/ajpgi.90405.2008. PMID:19299580.
7. Giaid, A., Yanagisawa, M., Langleben, D., Michel, R.P., Levy, R., Shennib, H., et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328(24): 1732-1739. doi:10.1056/NEJM199306173282402. PMID:8497283.
8. Horiuchi, I., Mori, Y.I., Taguchi, M., Ichida, F., Miyawaki, T., and Hashimoto, Y. 2009. Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction. Biopharm. Drug Dispos. 30(6): 326-333. doi:10.1002/bdd.671. PMID:19639656.
9. A receptor. J. Cardiovasc. Pharmacol. 20(Suppl 12): S11-S14. PMID:1282942.
10. Ishikawa, K., Ihara, M., Noguchi, K., Mase, T., Mino, N., Saeki, T., et al. 1994. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. U.S.A. 91(11): 4892-4896. doi:10.1073/pnas.91.11.4892. PMID:8197152.
11. Kamath, P.S., Tyce, G.M., Miller, V.M., Edwards, B.S., and Rorie, D.K. 1999. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology, 30(2): 401-407. doi:10.1002/hep.510300235. PMID:10421647.
12. Kohan, D.E. 1997. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 29(1): 2-26. doi:10.1016/S0272-6386(97)90004-4. PMID:9002526.
13. Kojima, H., Yamao, J., Tsujimoto, T., Uemura, M., Takaya, A., and Fukui, H. 2000. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J. Hepatol. 32(1): 43-50. doi:10.1016/S0168-8278(00)80188-9. PMID: 10673066.
14. Kojima, H., Sakurai, S., Kuriyama, S., Yoshiji, H., Imazu, H., Uemura, M., et al. 2001. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J. Hepatol. 34(6): 805-811. doi:10.1016/S0168-8278(01)00045-9. PMID: 11451162.
15. Kountouras, J., Billing, B.H., and Scheuer, P.J. 1984. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 65(3): 305-311. PMID:6743531.
16. Laleman, W., Landeghem, L., Wilmer, A., Fevery, J., and Nevens, F. 2005. Portal hypertension: from pathophysiology to clinical practice. Liver Int. 25(6): 1079-1090. doi:10.1111/j.1478-3231.2005.01163.x. PMID:16343056.
17. Mallat, A. 1998. Hepatic stellate cells and intrahepatic modulation of portal pressure. Digestion, 59(4): 416-419. doi:10.1159/000007501. PMID:9693221.
18. Mallat, A., Fouassier, L., Préaux, A.M., Gal, C.S., Raufaste, D., Rosenbaum, J., et al. 1995. Growth inhibitory properties of endothelin- 1 in human hepatic myofibroblastic Ito cells: an endothelin B receptor-mediated pathway. J. Clin. Invest. 96(1): 42-49. doi:10.1172/JCI118052. PMID:7615814.
19. Moreira, R.K. 2007. Hepatic stellate cells and liver fibrosis. Arch. Pathol. Lab. Med. 131(11): 1728-1734. PMID:17979495.
20. Poo, J.L., Jiménez, W., Muñoz, M.R., Bosch-Marcé, M., Bordas, N., Morales-Ruiz, M., et al. 1999. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology, 116(1): 161-167. doi:10.1016/S0016-5085(99) 70240-4. PMID:9869614.
21. Reichen, J., Gerbes, A.L., Steiner, M.J., Sägesser, H., and Clozel, M. 1998. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J. Hepatol. 28(6): 1020-1030. doi:10.1016/S0168-8278(98)80352-8. PMID:9672179.
22. Reinehr, R.M., Kubitz, R., Peters-Regehr, T., Bode, J.G., and Häussinger, D. 1998. Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. Hepatology, 28(6): 1566-1577. doi:10.1002/hep.510280617. PMID:9828221.
23. Rockey, D.C. 1995. Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Biochem. Biophys. Res. Commun. 207(2): 725-731. doi:10.1006/bbrc.1995.1247. PMID:7864865.
24. Rockey, D.C. 2000. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology, 118(6): 1261-1265. doi:10.1016/S0016-5085(00)70379-9. PMID:10833501.
25. Rothermund, L., Cho, J.J., Leggewie, S., Schwarz, A., Bauer, C., Paul, M., et al. 2000a. Activation of the hepatic endothelin-system in rats with biliary liver fibrosis. J. Cardiovasc. Pharmacol. 36(5 Suppl 1): S270-S273. PMID:11078396.
26. Rothermund, L., Leggewie, S., Schwarz, A., Thäne-Reinecke, C., Cho, J.J., Bauer, C., et al. 2000b. Regulation of the hepatic endothelin system in advanced biliary fibrosis in rats. Clin. Chem. Lab. Med. 38(6): 507-512. doi:10.1515/CCLM.2000.074. PMID:10987198.
27. Tran Duc, A.T., Schwab, A.J., Simard, A., Villeneuve, L., and Dupuis, J. 2003. Reduction in hepatic endothelin-1 clearance in cirrhosis. Clin. Sci. (Lond.), 105(2): 227-234. doi:10.1042/CS20030026. PMID:12708965.
28. Uchihara, M., Izumi, N., Sato, C., and Marumo, F. 1992. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology, 16(1): 95-99. doi:10.1002/hep.1840160117. PMID:1535610.
29. Watanabe, N., Takashimizu, S., Nishizaki, Y., Kojima, S., Kagawa, T., and Matsuzaki, S. 2007. An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation. J. Gastroenterol. 42(9): 775-782. doi:10.1007/s00535-007-2093-1. PMID: 17876548.
30. Weber, C., Schmitt, R., Birnboeck, H., Hopfgartner, G., van Marle, S.P., Peeters, P.A., et al. 1996. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol. Ther. 60(2): 124-137. doi:10.1016/S0009-9236(96)90127-7. PMID:8823230.
31. Williamson, D.J., Wallman, L.L., Jones, R., Keogh, A.M., Scroope, F., Penny, R., et al. 2000. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation, 102(4): 411-418. PMID:10908213.
32. Yokoyama, Y., Kawai, T., Kawai, S., Kitagawa, T., Watanabe, K., Kawai, K., and Nagino, M. 2008. Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to promote hepatic injury. Shock, 29(6): 688-691. PMID: 17885643.